Vaccine Therapy of B Cell Malignancies: Different Strategies for a Novel Approach

References

• Harris N. L., Jaffe E. S., Stein H., Banks P. M., Chan J. K., Cleary M. L., Delsol G., De Wolf-Peeters C., Falini B., Gaffer K. C. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–92
   PubMed Web of Science ®Google Scholar
• The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. New England Journal of Medicine 1993; 329: 987–94
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunology Today 1997; 18: 175–82
   PubMedGoogle Scholar
• Pardoll D. M. Cancer vaccines. Nat Med 1998; 4: 525–31
   PubMed Web of Science ®Google Scholar
• Bocchia M., Bronte V., Colombo M. P., De Vincentiis A., Di Nicola M., Forni G., Lanata L., Lemoli R. M., Massaia M., Rondelli D., Zanon P., Tura S. Antitumor vaccination: where we stand. Haematologica 2000; 85: 1172–206
   PubMed Web of Science ®Google Scholar
• Lynch R. G., Graff R. J., Sirisinha S., Simms E. S., Eisen H. N. Myeloma proteins as tumor-specific transplantation antigens. Proceedings of the National Academy of Science USA. 1972. 69: 1540–1544
   Google Scholar
• George A. J., Tutt A. L., Stevenson F. K. Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1. J Immunol 1987; 138: 628–34
   PubMed Web of Science ®Google Scholar
• Campbell M. J., Esserman L., Byars N. E., Allison A. C., Levy R. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. J Immunol 1990; 145: 1029–36
   PubMed Web of Science ®Google Scholar
• Campbell M. J., Esserman L., Levy R. Immunotherapy of established murine B cell lymphoma. Combination of idiotype immunization and cyclophosphamide. J Immunol 1988; 141: 3227–33
   PubMed Web of Science ®Google Scholar
• Kwak L. W., Pennington R., Boni L., Ochoa A. C., Robb R. J., Popescu M. C. Liposomal formulation of a self lymphoma antigen induces potent protective antitumor immunity. J Immunol 1998; 160: 3637–41
   PubMed Web of Science ®Google Scholar
• Kwak L. W., Young H. A., Pennington R. W., Weeks S. D. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proceedings of the National Academy of Science USA. 1996. 93: 10972–7
   Google Scholar
• Tao M. H., Levy R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 1993; 362: 755–8
   PubMed Web of Science ®Google Scholar
• Biragyn A., Tani K., Grimm M. C., Weeks S., Kwak L. W. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol 1999; 17: 253–8
   PubMed Web of Science ®Google Scholar
• King C. A., Spellerberg M. B., Zhu D., Rice J., Sahota S. S., Thompsett A. R., Hamblin T. J., Radl J., Stevenson F. K. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med 1998; 4: 1281–6
   PubMed Web of Science ®Google Scholar
• Kwak L. W., Campbell M. J., Czerwinski D. K., Hart S., Miller R. A., Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. New England Journal of Medicine 1992; 327: 1209–15
   PubMed Web of Science ®Google Scholar
• Hsu F. J., Caspar C. B., Czerwinski D., Kwak L. W., Liles T. M., Syrengelas A., Taidi-Laskowski B., Levy R. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma—long-term results of a clinical trial. Blood 1997; 89: 3129–35
   PubMed Web of Science ®Google Scholar
• Hsu F. J., Benike C., Fagnoni F., Lues T. M., Czerwinski D., Taidi B., Engleman E. G., Levy R. Vaccination of patients with B-cell lymphoma using autologous antigenpulsed dendritic cells. Nat Med 1996; 2: 52–8
   PubMed Web of Science ®Google Scholar
• Bendandi M., Gocke C. D., Kobrin C. B., Benko F. A., Sternas L. A., Pennington R., Watson T. M., Reynolds C. W., Gause B. L., Duffey P. L., Jaffe E. S., Creekmore S. P., Longo D. L., Kwak L. W. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999; 5: 1171–7
   PubMed Web of Science ®Google Scholar
• McCormick A. A., Kumagai M. H., Hanley K., Turpen T. H., Hakim I., Grill L. K., Tuse D., Levy S., Levy R. Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants. Proceedings of the National Academy of Science USA. 1999. 96: 703–8
   Google Scholar
• Osterroth E, Garbe A., Fisch P., Veelken H. Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells. Blood 2000; 95: 1342–9
   PubMed Web of Science ®Google Scholar
• Syrengelas A. D., Chen T. T., Levy R. DNA immunization induces protective immunity against B-cell lymphoma. Nat Med 1996; 2: 1038–41
   PubMed Web of Science ®Google Scholar
• Trojan A., Schultze J. L., Witzens M., Vonderheide R. H., Ladetto M., Donovan J. W., Gribben J. G. Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat Med 2000; 6: 667–72
   PubMed Web of Science ®Google Scholar
• Schultze J. L., Cardoso A. A., Freeman G. J., Seamon M. J., Daley J., Pinkus G. S., Gribben J. G., Nadler L. M. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proceedings of the National Academy of Science USA. 1995. 92: 8200–4
   Google Scholar
• Schultze J. L., Gribben J. G., Nadler L. M. Tumor-specific adoptive T-cell therapy for CD40+ B-cell malignancies. Current Opinion in Oncology 1998; 10: 542–7
   PubMedGoogle Scholar
• Levitsky H.I., Montgomery J., Ahmadzadeh M., Staveley-O'Carroll K., Guamieri F., Longo D. L., Kwak L. W. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7–1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J Immunol 1996; 156: 3858–65
   PubMed Web of Science ®Google Scholar
• Shtil A. A., Turner J. G., Durfee J., Dalton W. S., Yu H. Cytokine-based tumor cell vaccine is equally effective against parental and isogenic multidrug-resistant myeloma cells: the role of cytotoxic T lymphocytes. Blood 1999; 93: 1831–7
   PubMed Web of Science ®Google Scholar
• Hart D. N., Schultze J. L., Stewart A. K. Presentation of tumor antigens. Seminars in Hematology 1999; 36: 21–5
   PubMed Web of Science ®Google Scholar
• van Baren N., Brasseur F., Godelaine D., Hames G., Ferrant A., Lehmann F., Andre M., Ravoet C., Doyen C., Spagnoli G. C., Bakkus M., Thielemans K., Boon T. Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood 1999; 94: 1156–64
   PubMed Web of Science ®Google Scholar
• Treon S. P., Mollick J. A., Urashima M., Teoh G., Chauhan D., Ogata A., Raje N., Hilgers J. H.M., Nadler L., Belch A. R., Pilarski L. M., Anderson K. C. Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood 1999; 93: 1287–98
   PubMed Web of Science ®Google Scholar
• Li Y., Bendandi M., Deng Y, Dunbar C., Munshi N., Jagannath S., Kwak L. W., Lyerly H. K. Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. Blood 2000; 96: 2828–33
   PubMed Web of Science ®Google Scholar
• Bergenbrant S., Yi Q., Osterborg A., Bjorkholm M., Osby E., Mellstedt H., Lefvert A. K., Holm G. Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients. British Journal of Haematology 1996; 92: 840–6
   PubMed Web of Science ®Google Scholar
• Osterborg A., Yi Q., Henriksson L., Fagerberg J., Bergenbrant S., Jeddi-Tehrani M., Ruden U., Lefvert A. K., Holm G., Mellstedt H. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8-and CD4-specific T-cell responses. Blood 1998; 91: 2459–66
   PubMed Web of Science ®Google Scholar
• Reichardt V. L., Okada C. Y., Liso A., Benike C. J., Stockerl-Goldstein K. E., Engleman E. G., Blume K. G., Levy R. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma—a feasibility study. Blood 1999; 93: 2411–9
   PubMed Web of Science ®Google Scholar
• Liso A., Stockerl-Goldstein K. E., Auffermann-Gretzinger S., Benike C. J., Reichardt V., van Beckhoven A., Rajapaksa R., Engleman E. G., Blume K. G., Levy R. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biology of Blood and Marrow Transplantation 2000; 6: 621–7
   PubMed Web of Science ®Google Scholar
• Massaia M., Borrione P., Battaglio S., Mariani S., Beggiato E., Napoli P., Voena C., Bianchi A., Coscia M., Besostri B., Peola S., Stiefel T., Even J., Novero D., Boccadoro M., Pileri A. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood 1999; 94: 673–83
   PubMed Web of Science ®Google Scholar
• Borrello I., Sotomayor E. M., Ranis F. M., Cooke S. K., Gu L., Levitsky H. I. Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood 2000; 95: 3011–9
   PubMed Web of Science ®Google Scholar
• Timmerman J. M., Levy R. Dendritic cell vaccines for cancer immunotherapy. Annual Review of Medicine 1999; 50: 507–29
   PubMed Web of Science ®Google Scholar
• Banchereau J., Steinman R. M. Dendritic cells and the control of immunity. Nature 1998; 392: 245–52
   PubMed Web of Science ®Google Scholar
• Wen Y. J., Ling M., Bailey-Wood R., Lim S. H. Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clinical Cancer Research 1998; 4: 957–62
   PubMed Web of Science ®Google Scholar
• Lim S. H., Bailey-Wood R. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. International Journal of Cancer 1999; 83: 215–22
   PubMed Web of Science ®Google Scholar
• Titzer S., Christensen O., Manzke O., Tesch H., Wolf J., Emmerich B., Carsten C., Diehl V., Bohlen H. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. British Journal of Haematology 2000; 108: 805–16
   PubMed Web of Science ®Google Scholar
• Stevenson F. K., Link C. J., Jr., Traynor A., Yu H., Corr M. DNA vaccination against multiple myeloma. Seminars in Hematology 1999; 36: 38–42
   PubMed Web of Science ®Google Scholar
• Stevenson F. K., King C. A., Spellerberg M. B., Zhu D., Rice J., Sahota S., Thompsett A., Radl J., Hamblin T. J. DNA vaccines against haematological malignancies. Haematologica 1999; 84: 11–3
   PubMedGoogle Scholar
• Maecker H. T., Auffermann-Gretzinger S., Nomura L. E., Liso A., Czerwinski D. K., Levy R. Detection of CD4 T cell responses to a tumor vaccine by cytokine flow cytometry. Clinical Cancer Research 2001; 7((3 Suppl))902s–908s
   PubMed Web of Science ®Google Scholar
• Coiffier B. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma patients. Haematologica 1999; 84: 14–8
   PubMedGoogle Scholar
• Maloney D. G., Grillo-Lopez A. J., White C. A., Bodkin D., Schilder R. J., Neidhart J. A., Janakiraman N., Foon K. A., Liles T. M., Dallaire B. K., Wey K., Royston I., Davis T., Levy R. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188–95
   PubMed Web of Science ®Google Scholar
• Falini B., Terenzi A., Liso A., Flenghi L., Solinas A., Pasqualucci L. Targeted antibodies in the treatment of lymphomas. Cancer Surveys 1997; 30: 295–309
   PubMedGoogle Scholar
• Qin Z., Richter G., Schuler T., Ibe S., Cao X., Blankenstein T. B cells inhibit induction of T cell-dependent tumor immunity. Nat Med 1998; 4: 627–30
   PubMed Web of Science ®Google Scholar
• Davis T. A., Grillo-Lopez A. J., White C. A., McLaughlin P., Czuczman M. S., Link B. K., Maloney D. G., Weaver R. L., Rosenberg J., Levy R. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. Journal of Clinical Oncology 2000; 18: 3135–43
   PubMed Web of Science ®Google Scholar
• Ozaki S., Kosaka M., Wakahara Y., Ozaki Y., Tsuchiya M., Koishihara Y., Goto T., Matsumoto T. Humanized anti-HM1.24 antibody mediates myeloma cell cytotoxicity that is enhanced by cytokine stimulation of effector cells. Blood 1999; 93: 3922–30
   PubMed Web of Science ®Google Scholar
• Maloney D. G., Donovan K., Hamblin T. J. Antibody therapy for treatment of multiple myeloma. Seminars in Hematology 1999; 36: 30–3
   PubMed Web of Science ®Google Scholar
• Kwak L. W., Taub D. D., Duffey P. L., Bensinger W. I., Bryant E. M., Reynolds C. W., Longo D. L. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 1995; 345: 1016–20
   PubMed Web of Science ®Google Scholar
• Dianzani U., Pileri A., Boccadoro M., Palumbo A., Pioppo P., Bianchi A., Camponi A., Fossati G., Battaglio S., Massaia M. Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status. Blood 1988; 72: 1064–8
   PubMed Web of Science ®Google Scholar
• Yi Q., Osterborg A., Bergenbrant S., Mellstedt H., Holm G., Lefvert A. K. Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood 1995; 86: 3043–9
   PubMed Web of Science ®Google Scholar
• Yi Q., Eriksson I., He W., Holm G., Mellstedt H., Osterborg A. Idiotype-specific T lymphocytes in monoclonal gammopathies: evidence for the presence of CD4+ and CD8+ subsets. British Journal of Haematology 1997; 96: 338–45
   PubMed Web of Science ®Google Scholar